![Pablo Cironi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Pablo Cironi
Direttore/Membro del Consiglio presso Minoryx Therapeutics SL
Posizioni attive di Pablo Cironi
Società | Posizione | Inizio | Fine |
---|---|---|---|
Minoryx Therapeutics SL
![]() Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Direttore/Membro del Consiglio | 01/07/2019 | - |
Medlumics SL
![]() Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain. | Direttore/Membro del Consiglio | 01/02/2019 | - |
Aelix Therapeutics SL
![]() Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Direttore/Membro del Consiglio | 01/07/2019 | - |
Iproteos SL
![]() Iproteos SL Miscellaneous Commercial ServicesCommercial Services Iproteos SL engages in research and development for schizophrenia treatment. It specializes in the research and development of third-generation drugs for human diseases. The company was founded by Ernest Giralt and Teresa Tarragó and is headquartered in Barcelona, Spain. | Direttore/Membro del Consiglio | - | - |
GlyCardial Diagnostics SL
![]() GlyCardial Diagnostics SL Miscellaneous Commercial ServicesCommercial Services GlyCardial Diagnostics SL has developed a biomarker called iSCOR that can detect cardiac ischemia through a blood test. The company is based in Barcelona, Spain. Early detection of ischemia can prevent myocardial damage. The Spanish company was founded in 2017 by Rafols Judit Cubedo, Lina Badimon Maestro, Capmany Teresa Padro, and Gemma Vilahur. Rafols Judit Cubedo has been the CEO since 2017. | Direttore/Membro del Consiglio | 01/08/2019 | - |
Caixa Capital Risc SGEIC SA
![]() Caixa Capital Risc SGEIC SA Investment ManagersFinance Caixa Capital Risc SGEIC SA (Caixa Capital Risc) is a venture capital armof Criteria Caixa SA founded in 2002. The firm is headquartered in Barcelona, Spain with additional offices in Madrid. | Investitore di Private Equity | 01/09/2018 | - |
Storia della carriera di Pablo Cironi
Precedenti posizioni note di Pablo Cironi
Società | Posizione | Inizio | Fine |
---|---|---|---|
SpliceBio SL
![]() SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Direttore/Membro del Consiglio | 01/06/2019 | 01/01/2022 |
Sanifit Therapeutics SA
![]() Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Direttore/Membro del Consiglio | 01/07/2019 | 01/01/2022 |
AptaTargets SL
![]() AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Direttore/Membro del Consiglio | 01/08/2019 | 01/09/2020 |
░░░░░░ ░░░ ░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Pablo Cironi
Universidad de Buenos Aires | Graduate Degree |
University of Barcelona | Doctorate Degree |
Harvard Medical School | Doctorate Degree |
Statistiche
Distribuzione geografica
Spagna | 13 |
Argentina | 2 |
Stati Uniti | 2 |
Posizioni
Director/Board Member | 8 |
Doctorate Degree | 2 |
Corporate Officer/Principal | 2 |
Settori
Health Technology | 7 |
Consumer Services | 4 |
Commercial Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 11 |
---|---|
Minoryx Therapeutics SL
![]() Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Health Technology |
Medlumics SL
![]() Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain. | Health Technology |
Aelix Therapeutics SL
![]() Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Health Technology |
Iproteos SL
![]() Iproteos SL Miscellaneous Commercial ServicesCommercial Services Iproteos SL engages in research and development for schizophrenia treatment. It specializes in the research and development of third-generation drugs for human diseases. The company was founded by Ernest Giralt and Teresa Tarragó and is headquartered in Barcelona, Spain. | Commercial Services |
SpliceBio SL
![]() SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Health Technology |
Sanifit Therapeutics SA
![]() Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Health Technology |
GlyCardial Diagnostics SL
![]() GlyCardial Diagnostics SL Miscellaneous Commercial ServicesCommercial Services GlyCardial Diagnostics SL has developed a biomarker called iSCOR that can detect cardiac ischemia through a blood test. The company is based in Barcelona, Spain. Early detection of ischemia can prevent myocardial damage. The Spanish company was founded in 2017 by Rafols Judit Cubedo, Lina Badimon Maestro, Capmany Teresa Padro, and Gemma Vilahur. Rafols Judit Cubedo has been the CEO since 2017. | Commercial Services |
Fundación Botín | |
Centre For Genomic Regulation | |
AptaTargets SL
![]() AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Health Technology |
Caixa Capital Risc SGEIC SA
![]() Caixa Capital Risc SGEIC SA Investment ManagersFinance Caixa Capital Risc SGEIC SA (Caixa Capital Risc) is a venture capital armof Criteria Caixa SA founded in 2002. The firm is headquartered in Barcelona, Spain with additional offices in Madrid. | Finance |
- Borsa valori
- Insiders
- Pablo Cironi
- Esperienza